Table 2.
Clinicopathological characteristics group B.
| Variable | n = 253 | SARIFA-Positive (n = 79) | SARIFA-Negative (n = 174) | p-Value * | ||||
|---|---|---|---|---|---|---|---|---|
| Median Age [years] | 71 (61–77) | 72 (61–78) | 71 (61–77) | 0.658/1.0 | ||||
| Median Follow-up [years] | 4.2 (4.0–4.4) | 4.2 (3.9–4.5) | 4.2 (3.7–4.7) | 0.094/0.595 | ||||
| Median Lymph Node Harvest (n) | 38 (29–49) | 36 (28–53) | 39 (30–49) | 0.695/1.0 | ||||
| Positive Lymph Nodes (n) | 0 (0–2) | 1 (0–4) | 0 (0–1) | <0.001/0.009 | ||||
| Sex | 0.02/0.160 | |||||||
| female | 110 | 44% | 43 | 54% | 67 | 39% | ||
| male | 143 | 57% | 36 | 46% | 107 | 62% | ||
| T status | <0.001/0.009 | |||||||
| pT3 | 179 | 71% | 43 | 54% | 136 | 78% | ||
| pT4 | 74 | 29% | 36 | 46% | 38 | 22% | ||
| N status | <0.001/0.009 | |||||||
| negative | 144 | 57% | 25 | 32% | 119 | 68% | ||
| positive | 109 | 43% | 54 | 68% | 55 | 32% | ||
| Grading | 0.015/0.150 | |||||||
| low grade | 213 | 84% | 60 | 76% | 153 | 88% | ||
| high grade | 40 | 16% | 19 | 24% | 21 | 12% | ||
| Vascular Invasion | 0.016/0.150 | |||||||
| negative | 218 | 86% | 62 | 79% | 156 | 90% | ||
| positive | 35 | 14% | 17 | 21% | 18 | 10% | ||
| Lymphatic Vessel Invasion | <0.001/0.009 | |||||||
| negative | 197 | 78% | 50 | 63% | 147 | 85% | ||
| positive | 56 | 22% | 29 | 37% | 27 | 16% | ||
| Tumor Budding | <0.001/0.009 | |||||||
| Bd1 | 161 | 63% | 33 | 42% | 128 | 74% | ||
| Bd2 | 50 | 20% | 27 | 34% | 23 | 13% | ||
| Bd3 | 42 | 17% | 19 | 24% | 23 | 13% | ||
| Location | 0.785/1.0 | |||||||
| right | 139 | 55% | 42 | 53% | 97 | 56% | ||
| left | 114 | 45% | 37 | 47% | 77 | 44% | ||
| MSS | 0.580/1.0 | |||||||
| stable | 213 | 84% | 68 | 86% | 145 | 83% | ||
| instable | 40 | 16% | 11 | 14% | 29 | 17% | ||
| Adjuvant Chemotherapy | 0.009/0.108 | |||||||
| no | 164 | 65% | 42 | 53% | 122 | 70% | ||
| yes | 89 | 35% | 37 | 47% | 52 | 30% | ||
| Distant Metastasis | <0.001/0.009 | |||||||
| no | 192 | 76% | 48 | 61% | 144 | 83% | ||
| yes | 61 | 24% | 31 | 39% | 30 | 17% | ||
| Death | 0.009/0.108 | |||||||
| no | 185 | 73% | 49 | 62% | 136 | 78% | ||
| death | 68 | 27% | 30 | 38% | 38 | 22% | ||
| Colon-Cancer-Specific Survival | 0.105/0.595 | |||||||
| no | 229 | 90% | 68 | 86% | 161 | 92% | ||
| death | 24 | 10% | 11 | 14% | 13 | 8% | ||
| Five Year Survival (n = 117) | 0..085/0.595 | |||||||
| survived | 65 | 56% | 20 | 44% | 45 | 63% | ||
| death | 52 | 44% | 25 | 56% | 27 | 38% | ||
Legend: 95% CI, 95% confidence interval; p-values are shown for difference between SARIFA (Stroma AReactive Invasion Front Areas) positive and SARIFA-negative tumors; Abbreviations: MSS: microsatellite stability status; * adjusted using Bonferroni Holm method [37].